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INTRODUCTION
Trichosporon spp. are basidiomycetous yeast-like anamor-
phic organisms (Basidiomycota, Hymenomycetes, Tremelloi-
dae, Trichosporonales) that are widely distributed in nature
and found predominantly in tropical and temperate areas.
These organisms can be found in substrates such as soil, de-
composing wood, air, rivers, lakes, seawater, cheese, scarab
beetles, bird droppings, bats, pigeons, and cattle. In humans,
these fungal species occasionally are part of the gastrointesti-
nal and oral cavity microbiota and can transiently colonize the
respiratory tract and skin (22, 60, 68, 76, 101, 108, 170, 186,
188, 189). Recently, Silvestre et al. found that 11% of their
1,004 healthy male volunteers were colonized by Trichosporon
species on their normal perigenital skin (scrotal, perianal, and
inguinal sites of the body) (165).
The genus Trichosporon is phenotypically characterized by
the ability to form blastoconidia, true mycelia, and, most im-
portantly, arthroconidia, asexual propagules that disarticulate
from true hyphae. The presence of multilamellar cell walls and
dolipores with or without parenthesomes is an important char-
acteristic of Trichosporon spp. (66, 69). Nevertheless, some
species possess other morphological structures that can also be
used to differentiate them, including appresoria, macroconidia,
or other morphological structures and processes. Trichosporon
spp. are able to utilize different carbohydrates and carbon
sources and to degrade urea, but members of this genus are
nonfermentative. Cell cultures grow on Sabouraud dextrose
agar as yeast colonies with colors ranging from white to cream,
typically displaying aspects such as cerebriform and radial sur-
faces (39). Colonies may become dry and membranous with
age (101).
The genus Trichosporon has a long and controversial history.
It was first designated in 1865 by Beigel, who observed this
microorganism causing a benign hair infection. The word Tri-
chosporon is derived from the Greek and represents a combi-
nation of Trichos (hair) and sporon (spores). This nomencla-
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ture is related to the presence of irregular nodules along the
body and head hair, consisting of a fungal infection, which is
further characterized as white piedra (meaning “stone” in
Spanish). Indeed, the etiological agent of this white piedra was
formerly misclassified as the alga Pleurococcus beigelii (66, 69).
In 1890, Behrend described the agent causing white piedra
found on a man’s beard in detail and named it Trichosporon
ovoides (16). Since then, other Trichosporon species have been
reported. In 1902, Vuillemin designated all Trichosporon spe-
cies Trichosporon beigelii, an arthrospore-containing yeast
(66, 69).
In 1909, Beurmann et al. cultured fungal elements collected
from a patient with a pruritic cutaneous lesion and designated
the isolated fungus Oidium cutaneum, which was subsequently
renamed Trichosporon cutaneum by Ota in 1926. Nevertheless,
in 1942 Diddens and Lodder considered T. beigelii and T.
cutaneum to be the same species. This led to the use of two
names for this fungus with clinical relevance: Trichosporon
beigelii, adopted by physicians, and Trichosporon cutaneum,
preferred by environmental mycologists (66, 69).
Although most Trichosporon spp. routinely isolated in labo-
ratories are related to episodes of colonization or superficial
infections, this fungus has been recognized as an emergent
opportunistic agent causing invasive infections in tertiary care
hospitals worldwide (25).
The genus Blastoschizomyces, which contains a unique spe-
cies named B. capitatus, was also considered to belong to the
Trichosporon genus in the past. It has been recognized as a rare
but emerging cause of disseminated infection specifically in
leukemic patients (32). B. capitatus was thereafter reassigned
to the genus Geotrichum (Geotrichum capitatus), but since 1985
the species has been recognized as more closely related to the
Ascomycetes despite the fact it produces blastoconidia and
arthroconidia just like Trichosporon (157). Indeed, B. capitatus
has a well-described teleomorph named Dipodascus capitatus
which produces asci and ascospores (38). In addition, it pro-
duces annelloconidia, a distinct cell wall composition, and sep-
tal pores, peculiar characteristics that make it different from
the genera Trichosporon and Geotrichum (157).
CURRENT TAXONOMY OF TRICHOSPORON SPP.
Traditional taxonomy based on phenotypic characterization
of fungal organisms generates inconsistent data when applied
to the genus Trichosporon, as it aggregates within the same
taxon isolates with genetically heterogeneous behavior. In
1982, some strains belonging to the taxon T. beigelii were found
to possess a Q-10 ubiquinone system, while others contained a
Q-9 system (192). Since then, several authors have reported
clear differences among T. beigelii isolates based on physiolog-
ical, morphological, and genetic characteristics.
In 1991, Kemker et al. started to describe clearly the diver-
sity among Trichosporon spp. isolated from environmental and
clinical sources (94). These authors evaluated different isoen-
zymes present in 15 Trichosporon strains and the genetic pro-
files of these strains by using restriction fragment length poly-
morphisms (RFLP) analysis of ribosomal DNA (rDNA),
including both the internal transcribed spacer 1 (ITS1) and
ITS2 regions and the 5.8S gene as targets. These data were
compared with morphological features, carbon substrate usage
profiles, and uric acid assimilation abilities.
In 1992, Gueho and collaborators conducted molecular
studies of nucleic acids correlated with the morphological,
physiological and biochemical characteristics of a collection of
strains and proposed the reassignment of the genus Tricho-
sporon (69). The criteria used to reclassify Trichosporon species
were based on several aspects, including the ultrastructure of
septal pores. These authors demonstrated that although all
Trichosporon species contain an electron-dense and multila-
mellar cell wall, at least two basic types of dolipores exist. The
first is composed of nailhead-like swellings separated by a
narrow pore canal that is often filled by an electron-dense
mass, whereas the second is constituted by well-defined,
rounded inflations with a sponge-like or vesicular substructure
covered by a parenthesome. Other characteristics, such as co-
enzyme Q systems Q-10 and Q-9, differed within Trichosporon
spp. and corresponded to the guanine-plus-cytosine content
(moles percent GC). DNA reassociation values, nutritional
profiles, and evaluation of part of the 28S regions of rDNA
sequences also demonstrated differences between Tricho-
sporon species. Following analysis of 101 strains, these authors
described a new species (Trichosporon mucoides) and 19 taxa;
additionally, some previously described species were desig-
nated synonyms of other species.
In the same year, Gueho et al. reported on the variety of the
genus and suggested that various series of species can be rec-
ognized based upon different niches (66). Strains differ based
on their source of isolation (soil, water, or human or animal
disease) and based on their phenotypic and molecular proper-
ties. The two species T. beigelii and T. cutaneum, considered to
be synonyms since 1942, were clearly different as determined
by ubiquinone systems and percent GC DNA content.
Therefore, the authors considered the nomenclature T. beigelii
to be inappropriate and suggested that it be abandoned. In
1994, those authors concluded that the genus Trichosporon
should include the following six species: T. cutaneum, T. asahii,
T. asteroides, T. mucoides, T. inkin and T. ovoides (67).
Therefore, the previous taxon T. beigelii was replaced by
several species, and the taxonomy of the genus was progres-
sively modified by powerful molecular tools able to discrimi-
nate between phylogenetically closely related species (66, 176,
177). In 1994 and 1995, Sugita et al. reviewed the genus Tri-
chosporon and proposed a new classification including 17 spe-
cies and 5 varieties of Trichosporon (176, 177). In 2002, Sugita
et al. proposed 25 species for the genus Trichosporon and
suggested that 8 should be considered relevant as potential
human pathogens, including the two emergent species T. do-
mesticum and T. montevideense (172). Thereafter, the same
group published a report in 2004 recognizing 36 Trichosporon
species, including 5 new species proposed by Middlehoven et
al. in 2004: T. vadense, T. smithiae, T. dehoogii, T. scarabaeo-
rum, and T. gamsii (169). In 2004, Middlehoven et al. also
separated the order Trichosporonales into four clades named
Gracile, Porosum, Cutaneum, and Ovoides (Table 1) (123). In
that same year, Sugita et al. (169) included the clade Brassicae
in the order Trichosporonales, which encompassed some spe-
cies considered to belong to the Gracile clade by Middlehoven
et al. (123) (Table 1).
A new Trichosporon species isolated from the hindgut of the
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lower termite Mastotermes darwiniensis, recognized as an im-
portant detoxifier of mycotoxins, was described by Molnar et
al. in 2004 and named T. mycotoxinivorans, belonging to the
clade Gracile (125).
In 2005, a study addressing the isolation and identification of
yeasts from guano of bat-inhabited caves in Japan proposed
seven novel potential Trichosporon species. The new species
were not representative of a single clade (Gracile, Porosum,
Brassicae, Cutaneum, or Ovoides) but were distributed across
all but the Ovoides clade (170). In 2008, Fuentefria proposed
a new Trichosporon species isolated from the guts of insects
from Panama and from artesian cheese prepared in Brazil. The
new species was included in the Ovoides clade (60).
In 2009, a new Trichosporon species was described in Qatar.
Taj-Aldeen et al. described a novel Trichosporon species
named T. dohaense following the investigation of 27 clinical
isolates of Trichosporon obtained from immunosuppressed pa-
tients. Three isolates of the new species were cultured from
patients with onychomycosis, catheter-related infection, and
tinea pedis. The novel species is closely related to T. coremii-
forme and belongs to the Ovoides clade (180).
In 2010, in Brazil, a new Trichosporon species was described
based on the analysis of the D1/D2 and ITS regions of 34
Trichosporon strains closely related to T. scarabaeorum. The
new species was named T. chiarelli, and strains were isolated
from a fungus garden and from waste. This novel species was
considered a sibling species of the Cutaneum clade (139).
Recently, other Trichosporon species have been described.
The first species was originally cultured from the gut of the
wood-resident beetle Xylopinus saperdioides and named T. xy-
lopini. It is clearly distinguishable from its closest relative, T.
porosum, by 14 nucleotides in the ITS and D1/D2 regions of
the rRNA genes. Of note, T. xylopini has been recognized as an
arthroconidium-producing yeast that is able to degrade hemi-
cellulose (71). Two other novel Trichosporon species were
characterized based on the analysis of oleaginous yeasts main-
tained at the American Type Culture Collection (ATCC My-
cology Collection). They were named T. cacaoliposimilis and T.
oleaginosus, respectively. Molecular phylogenetic analyses
showed that T. cacaoliposimilis belongs to the Gracile clade,
close to T. gracile and T. dulcitum, whereas T. oleaginosus
belongs to the Cutaneum clade, with T. jirovecii as the closest
taxon (70).
In conclusion, as illustrated in Table 1, 50 species of Tricho-
sporon have been described from different regions of the globe,
including 16 species with clinical relevance (139). The previ-
ously recognized taxon T. pullulans, which was considered to
belong to the genus Trichosporon by Diddens and Lodder in
1942, has now been reassigned to a new genus and is named
Guehomyces pullulans (51).
Based on the large variability of natural habitats related to
all different species of Trichosporon, it is possible to suggest
that different reservoirs may play a role in human infections.
VIRULENCE FACTORS OF TRICHOSPORON SPP. AND
SOURCES OF INVASIVE INFECTIONS
Fungi that are opportunistic pathogens retain several factors
that allow their growth and permit the establishment of disease
and their dissemination within the host. These factors are
known as virulence factors. Such factors are usually related to
morphological switching, the ability to adhere to abiotic sur-
faces, thermotolerance, the expression of cell wall components,
and enzyme production and secretion (77, 87, 145). Even
though Trichosporon spp. can represent the second or third
most common non-Candida yeast infections causing invasive
disease in patients with hematological cancer, few reports have
addressed the virulence factors of this genus (24, 42, 138).
TABLE 1. Currently accepted Trichosporon species and their
subdivision within different clades
Clade Species no. Species namea
Gracile/Brassicae 1 Trichosporon brassicae
2 Trichosporon domesticum
3 Trichosporon montevideense
4 Trichosporon scarabaeorum
5 Trichosporon mycotoxinivorans
6 Trichosporon dulcitum
7 Trichosporon cacaoliposimilis
8 Trichosporon gracile
9 Trichosporon laibachii
10 Trichosporon multisporum
11 Trichosporon vadense
12 Trichosporon veenhuisii
13 Trichosporon akiyoshidainum
14 Trichosporon chiropterorum
15 Trichosporon siamense
16 Trichosporon otae
17 Trichosporon loubieri
Cutaneum 18 Trichosporon cutaneum
19 Trichosporon debeurmannianum
20 Trichosporon dermatis
21 Trichosporon jirovecii
22 Trichosporon oleaginosus
23 Trichosporon moniliiforme
24 Trichosporon mucoides
25 Trichosporon smithiae
26 Trichosporon terricola
27 Trichosporon middelhovenii
28 Trichosporon shinodae
29 Trichosporon cavernicola
Porosum 30 Trichosporon aquatile
31 Trichosporon asahii
32 Trichosporon asteroides
33 Trichosporon caseorum
34 Trichosporon coremiiforme
35 Trichosporon faecale
36 Trichosporon inkin
37 Trichosporon japonicum
38 Trichosporon lactis
39 Trichosporon ovoides
40 Trichosporon insectorum
41 Trichosporon porosum
42 Trichosporon dohaense
43 Trichosporon chiarellib
44 Trichosporon xylopini
Ovoides 45 Trichosporon dehoogii
46 Trichosporon gamsii
47 Trichosporon guehoae
48 Trichosporon lignicola
49 Trichosporon sporotrichoides
50 Trichosporon wieringae
a The species in bold were described as being of medical interest.
b Closely related but placed in a different clade by Pagnocca et al. (139).
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Biofilms
Infections with invasive Trichosporon spp. are usually asso-
ciated with central venous catheters, vesical catheters, and
peritoneal catheter-related devices. The ability to adhere to
and form biofilms on implanted devices can account for the
progress of invasive trichosporonosis, as it can promote the
escape from antifungal drugs and host immune responses. Di
Bonaventura et al. were the first to use electron microscopy to
analyze the kinetics of biofilm formation and development on
polystyrene surfaces. They tested 4 T. asahii strains, 3 of which
were isolated from blood samples of patients with hematolog-
ical malignancies (42). Those authors showed that, similarly to
data described for biofilms of Candida spp., T. asahii cells were
able to rapidly adhere to polystyrene after a 30-min incubation.
These cells presented different morphologies, such as budding
yeasts and filamentous forms, embedded within an extracellu-
lar polysaccharide (EPS) matrix composing the ultrastructure
of the mature biofilm after 72 h. Analysis of confocal imaging
sections taken across the biofilm showed that the thickness of
mature biofilms varied from 25 to 40 m. These authors also
tested the susceptibility profiles of planktonic and biofilm cells
to amphotericin B, caspofungin, fluconazole, and voriconazole.
T. asahii biofilms were resistant to all antifungals tested
(MIC  1,024 g/ml) and were up to 16,000 times more re-
sistant to voriconazole than planktonic cells (MIC  0.06
g/ml).
Enzymes
Another important virulence factor is the ability to produce
and secrete enzymes for scavenging nutrients from the envi-
ronment. Proteases and phospholipases are among the en-
zymes that can increase fungal pathogenicity by breaking up
proteins and disrupting host cell membranes, depending on
their expression levels and the host immune response (61).
In 1994, Chen and collaborators purified two lipase enzymes
(lipases I and II) from T. fermentans WU-C12 and verified that
these enzymes could hydrolyze olive oil with an optimum pH of
5.5 and temperature of 35°C (31). These lipases also demon-
strated stable activity after incubation at 30°C for 24 h over a
pH range of 4.0 to 8.0 and were further characterized by cDNA
isolation and sequencing (7). BLAST (Basic Local Alignment
Search Tool, http://blast.ncbi.nlm.nih.gov/) analysis showed
that the cDNA encoded by the gene TFL1 and the putative
protein sequence had 99.5% similarity to those of lipase II
from Geotrichum candidum. Southern blot analysis revealed
that there were two lipase genes carried on the genome, con-
firming the prior purification of two lipases. A putative corre-
lation between the ability to produce Tfl1 lipase and the viru-
lence of Trichosporon in humans has not been examined.
However, one can speculate that lipases in general are impor-
tant for the invasion process and for adaptation to different
tissues within the host.
With regard to Trichosporon spp. isolated from infected pa-
tients, Chaves and collaborators have analyzed the proteinase
and phospholipase activities of a collection of 30 yeast isolates,
including two strains of T. pullulans (30). Both of the T. pul-
lulans isolates did not exhibit phospholipase activity but did
display proteinase activity. This result is reasonable in light of
the reclassification of T. pullulans as Guehomyces pullulans,
which could be a phospholipase nonproducer.
Dag and Cerikc¸ioglu analyzed the production of a variety of
virulence factors from 50 T. asahii strains, the majority of
which were isolated from urine, although some originated each
from blood, peritoneal fluid, nephrostomy, tongue swab, and
nail. Proteinase and phospholipase activities could not be de-
tected from these strains, although all isolates were esterase
positive. Slime production was moderate in 10 strains, while 18
strains were characterized as weak producers and 20 strains
were defined as slime nonproducers (37).
Later, Cafarchia and collaborators investigated the phos-
pholipase activity in a collection of 163 yeast isolates recovered
from pigeon cloacae and droppings (22). Biochemical and
morphological tests identified 13 species among these isolates,
of which 14 isolates were identified as T. beigelii. Two of the 10
isolates recovered from cloacae exhibited phospholipase activ-
ity in egg yolk medium plates after 2 and 5 days of incubation,
whereas all 4 isolates from excreta exhibited phospholipase
activity. This was the first report showing phospholipase activ-
ity in Trichosporon spp., and no gene in the genome has been
described to have this function.
Recently, an alkaline lipase was isolated from T. asahii MSR
54, which was previously cultured from petroleum sludge in
India for application in developing a presoak formulation for
oil removal (100). The enzyme was active at ambient temper-
ature but presented maximal activity at 40°C and over a pH
range of 8.0 to 10.0. An analysis of the production of extracel-
lular enzymes and the morphology switch of 61 clinical isolates
of T. asahii revealed that these isolates were not able to pro-
duce secreted aspartic proteinases or phospholipases, while
they were able to secrete active beta-N-acetylhexosaminidase.
No other clinically relevant Trichosporon spp. have been shown
to produce this enzyme (84). The same study also reported 4
different morphological types of colonies grown on Sabouraud
dextrose agar (SDA), i.e., white farinose (69%), white pustular
(18%), yellowish white (10%), and white cerebriform (3%).
Those authors observed that strains of the three major types
usually developed two to five colony types and switched at a
frequency of 102 to 104 when grown at 37°C, similar to that
observed with Candida albicans and Cryptococcus neoformans
(4, 59, 87). Most of the colonies switched irreversibly to the
smooth type, which had the greatest beta-N-acetylhexosamini-
dase enzymatic activity compared with the parent type in all
strains (84).
Despite the available information on the capability of Tri-
chosporon strains to produce lipases and proteases, the roles of
these enzymes in the pathogenesis of human invasive infec-
tions are not clear. In addition, this genus may possess cryptic
enzymes not yet described.
Cell Wall Components
Members of Trichosporon spp. express glucuronoxyloman-
nan (GXM) in their cell walls, similarly to C. neoformans.
GXM is a 1,3-linked mannan backbone attached to short side
chains of 1,4-linked mannose and 1,2-linked xylose residues by
substituting the 2 or 4 portion of the 1,3-linked mannose res-
idues of the main group (124). This polysaccharide may atten-
uate the phagocytic capability of neutrophils and monocytes in
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vivo (150). Karashima and collaborators reported that T. asahii
isolates could switch phenotype and increase the amount of
secreted GXM after passage in a mouse model (91). Three
environmental isolates were analyzed before and after consec-
utive passages through mice and compared with 14 isolates
from patients with deep-seated infections or recovered from
lung autopsies, blood, urine, sputum, and catheters. That study
demonstrated that the colonies of all of the environmental
isolates were rugose, whereas the majority of the clinical iso-
lates were powdery when grown on SDA. The clinical isolates
consisted of 90% blastoconidia and arthroconidia, whereas all
of the environmental isolates consisted of 99% hyphae. Inter-
estingly, all environmental isolates from mouse kidneys recov-
ered in SDA switched their macromorphologies to powdery
colonies, with conidia as the predominant cell type. All clinical
isolates released significantly higher levels of GXM than did
environmental isolates (titers of log2 9.4 0.7 versus log2 5.4
1.4). After passage in mice, environmental isolates generated
increased GXM concentrations (titers of log2 10.0 0.7 versus
log2 5.4  1.4). Minor changes in the (133)--D-glucan
(BDG) titers were observed, and no significant difference in
titers was detected for environmental isolates before and after
passage in mice. Taken together, the changes in the phenotype
of the environmental isolates after passages in mice seem to be
a regular response to adaptation within the host in order to
facilitate dissemination and escape from phagocytosis by poly-
morphonuclear leukocytes and monocytes in vivo.
The protective role of GXM was also addressed by analyzing
the structure and function of GXM isolated from T. asahii and
testing whether this polysaccharide could protect acapsular C.
neoformans mutants from phagocytosis by mouse macro-
phages. Fonseca and collaborators reported that the concen-
tration of GXM in the supernatants of T. asahii cultures was
approximately 12 times less than that in C. neoformans super-
natants (56). The major components of T. asahii GXM were
mannose (60%), followed by xylose (24%) and glucose (8%).
This differed from the case for C. neoformans supernatants,
from which the third most commonly isolated component was
glucuronic acid (10%). Fluorescence microscopy also demon-
strated that T. asahii cells possessed less GXM in their cell
walls than C. neoformans cells. To test the protective effect of
GXM against phagocytosis, acapsular C. neoformans mutant
cells were coated with GXM purified from a C. neoformans
high-GXM producer and with GXM from T. asahii and incu-
bated with murine macrophage cells in vitro. Yeast cells con-
taining no detectable surface GXM were rapidly internalized
by phagocytes, and the polysaccharide-coated cells were
phagocytized 6 times less frequently. However, no significant
difference was observed with regard to the GXM source, indi-
cating that despite differences in major sugar components,
GXM from T. asahii had a protective role similar to that of
GXM from C. neoformans (56, 84).
Sources of Superficial and Invasive Infections
The source of superficial and deep-seated Trichosporon in-
fections is still the subject of considerable debate. It is impor-
tant to consider that Trichosporon spp. are widely distributed in
nature and may be part of the normal biota of the skin, respi-
ratory tract, gastrointestinal tract, and vagina (24, 187).
The mode of transmission of superficial trichosporonosis
remains unclear, but poor hygiene habits, bathing in contam-
inated water, and sexual transmission may play a role (17, 96).
Although there is no consensus on the route of infection of
human beings, close contact with an incident case, hair humid-
ity, and the length of the scalp hair have all been recognized as
risk factors for acquiring white piedra (96, 153, 158, 197).
In regard to deep-seated infections, gastrointestinal coloni-
zation and further translocation throughout the gut may be
considered the source of infection in a considerable number of
episodes of trichosporonosis documented in cancer patients. In
support of an endogenously acquired route of infection, we
may look to evidence in support of gut translocation as the
major source of candidemia, a biological model that may ex-
plain invasive infections caused by yeast pathogens that colo-
nize the gastrointestinal tract (34, 134). In developing the first
animal model of invasive trichosporonosis, Walsh and col-
leagues showed that Trichosporon was able to disseminate from
the gut to the blood and other organs in rabbits after immu-
nosuppression but not in healthy animals (189).
In addition to endogenous acquisition from the gut, evi-
dence also suggests that a substantial number of tricho-
sporonosis cases may be exogenously acquired. Trichosporon
spp. may enter the blood after contamination of a percutane-
ously inserted intravascular catheter via colonized skin. In-
deed, Kontoyiannis et al. evaluated 17 cancer patients with
trichosporonosis and suggested that central venous catheter-
related fungemia was the cause of 70% of all episodes (98).
Interestingly, those authors suggested that prophylaxis with
fluconazole, frequently used in patients with hematological
disease, may prevent the gut translocation of Trichosporon spp.
in this population, making the exogenous acquisition of this
pathogen (i.e., mediated by colonization of a central venous
catheter) the most plausible source of infection in this specific
population.
Finally, infants with very low birth weight (VLBW) may
develop trichosporonosis, despite it being a rare cause of sepsis
in neonates. Either yeast gastrointestinal translocation or cath-
eter-associated fungemia may occur in these patients. Neonate
skin colonization by Trichosporon may be acquired either from
health care workers or after vaginal delivery, as up to 14% of
woman may harbor this organism in their vulvovaginal region
(45, 156).
HUMAN INFECTIONS CAUSED BY MEMBERS OF THE
GENUS TRICHOSPORON: AT-RISK POPULATIONS
AND CLINICAL MANIFESTATIONS
Trichosporon is a medically important genus whose members
are able to colonize and proliferate in different parts of human
body, including the gastrointestinal system, respiratory tract,
skin, and vagina. This yeast-like pathogen may cause deep-
seated, mucosa-associated, or superficial infections. Invasive
trichosporonosis is documented mostly in patients with hema-
tological malignancies and other medical conditions associated
with immunosuppression, whereas superficial infections and
allergic pneumonia are found predominantly in immunocom-
petent hosts (24, 46, 98, 184). Table 2 summarizes the sources
of infection, main associated conditions, and etiological agents
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that are involved with the most clinically relevant Trichosporon
infections.
Superficial Infections
The clinical presentation of Trichosporon infection in hu-
mans is often benign superficial lesions of hair, called white
piedra, characterized by the presence of irregular nodules on
the affected hair. These nodules are loosely attached to the
hair shaft, have a soft texture, and may be white or light brown.
White piedra is a cosmopolitan disease affecting children and
adults from areas with tropical and temperate climates. Most
cases of white piedra have been reported in children and young
adults, particularly females who frequently use headbands. Al-
though rarely reported in the United States, this disease may
be found in Texas and may be underreported in several regions
(63, 96, 159).
White piedra may be found in a large variety of hairy re-
gions, including the scalp, beard, moustache, eyebrows, axilla,
and, particularly, genital hairs. Concomitant hair infection by
Trichosporon spp. and corynebacteria has been demonstrated
by electron microscopy and histochemical evaluation of con-
cretions, and it is still unclear whether the proteolytic capabil-
ities of the coryneform bacteria may be relevant for the estab-
lishment of fungal infection (53, 54, 65, 67, 92, 96, 177, 197).
White piedra appears to be caused predominantly by T.
inkin, T cutaneum, T. ovoides, and T. loubieri, which has re-
cently been reported in the literature as an emergent species
related mainly to superficial infections in humans (9, 67, 99,
137, 177). It is noteworthy that Trichosporon spp. can also
cause other superficial infections, such as onychomycosis,
where the more frequently isolated species is T. cutaneum.
Indeed, some Mexican authors have documented that the
isolation of Trichosporon spp. from tinea pedis and onychomy-
cosis patients may range from 2.81% to 42.8% of cases (9, 121,
155).
Deep-Seated Infections
After the first case of invasive trichosporonosis described by
Watson and Kallichurum in 1970 (190a), several cases of in-
vasive trichosporonosis in different clinical scenarios were de-
scribed. For instance, in 1982 Manzella et al. reported a case of
fungemia with cutaneous dissemination due to a Trichosporon
sp. documented in a leukemic patient followed until death
(113). Some years later, in 1988, Reinhart et al. reported a case
of endocarditis caused by a Trichosporon sp. in a patient who
had previously suffered from rheumatic disease (148). In 1997,
Lopes et al. described a case of peritonitis due to T. inkin in a
diabetic patient (107). In 2001, Moretti-Branchini et al. re-
ported 2 cases of invasive Trichosporon infections involving 2
patients with bone marrow transplants hospitalized at the Clin-
ical Hospital of The University of Campinas, Brazil (126). A
case of chronic dissemination infection due to a Trichosporon
sp. resulting in multiple liver abscesses was reported by Meyer
et al. in 2002 (122). In 2005, Abdala et al. reported a case of
invasive T. asahii infection in a nonneutropenic patient under-
going orthotopic liver transplantation who died despite treat-
ment with amphotericin B (1).
After combining all of the reported cases of trichosporono-
sis, one can suggest that Trichosporon spp. appear to be in-
creasing agents of invasive mycoses in contemporary medicine.
In patients with malignant hematological diseases, this genus
has been reported as the second most common agent of dis-
seminated yeast infections, behind only the genus Candida,
leading to 50 to 80% mortality rates despite treatment with
antifungal therapy (55, 99, 138, 188). Indeed, breakthrough
trichosporonosis in immunocompromised patients after ad-
ministration of amphotericin B and echinocandins, and more
rarely after the use of triazoles, has been extensively reported
(15, 64, 79, 118, 186).
The largest retrospective multicenter study of invasive tri-
chosporonosis and geotrichosis in patients with malignant he-
matological diseases was conducted by Girmenia et al. in 2005
and included data on Trichosporon and Geotrichum infections
documented over 20 years (62). Those authors reviewed 287
cases of trichosporonosis and 99 cases of geotrichosis docu-
mented from all over the world. The most common underlying
conditions related to trichosporonosis were hematological dis-
eases, peritoneal dialysis, and solid tumors. Trichosporonemia
occurred in 115/154 (74.7%) of patients and disseminated in-
fection in 78/154 (50.6%) of cases. The majority of the cases of
trichosporonosis and geotrichosis were reported in North
American medical centers (33.9%), followed by medical cen-
ters from Europe (27.6%) and Asia (23.3%). Only 6 isolates
from South American institutions were reported, including 5
Brazilian isolates and 1 isolate from Argentina. Despite the
large number of Trichosporon isolates included in this review,
two were accurately identified to the species level as T. loubieri
and 8 were assigned to the old taxon T. pullulans (recently
named G. pullulans), while the other 287 isolates were identi-
fied only as Trichosporon sp.
In 2004, Kontoyannis et al. described the clinical spectrum
and outcome of 17 patients with cancer and invasive tricho-
TABLE 2. Human trichosporonosis: sources of infection, main associated conditions, and etiological agents
Infection category Main type(s) of infection Major agent(s) Main associated conditions
Invasive Fungemia, urinary tract infections,
peritonitis, endocarditis, othersa
T. asahii, T. mucoides, T. asteroides Cancer, vascular and urinary catheters, organ
transplantation, broad-spectrum antibiotic
therapy
Allergic pneumonia Summer-type hypersensitivity
pneumonitis
T. cutaneumb Hot and humid weather, environmental
contamination
Superficial White piedra T. inkin, T. cutaneum, T. ovoides,
T. loubieri
Young age and female sex, long hair,
humidity, poor hygiene, headband use
a Arthritis, esophagitis, meningitis, brain abscess, splenic abscess, and uterine infections.
b T. cutaneum is now considered a complex of 10 different species.
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sporonosis documented at the MD Anderson Cancer Center.
The overall incidence of invasive trichosporonosis was found to
be 8 cases per 100,000 admitted patients; 65% of the infected
patients had acute leukemia, and 65% had neutropenia. Most
patients (59%) had fungemia as the sole manifestation of the
fungal infection, and 7 of 10 with Trichosporon fungemia had a
central venous catheter-related infection. Of note, 60% of ep-
isodes were documented in patients who had been exposed to
at least 7 days of antifungal therapy (breakthrough infections).
The crude mortality rate at 30 days after admission was 53%
(98).
In 2009, Ruan et al. described a series of 19 patients with
invasive trichosporonosis documented between 2000 and 2008
at the National Taiwan University Hospital. Cancer was the
underlying disease in 58% of patients, and only 4 patients
(21%) were neutropenic at the time of the diagnosis. Central
venous catheter placement and the use of antibiotics were the
most commonly associated conditions, being present in 90%
and 95% of all patients, respectively. The crude mortality rate
at 30 days after infection was 42% (154).
In 2010, Suzuki et al. retrospectively evaluated clinical as-
pects and outcomes for 33 patients with Trichosporon fungemia
and hematological malignancies in 5 different Japanese tertiary
care centers between 1992 and 2007. The majority of these
patients had acute leukemia (82%) and neutropenia (85%),
and 90% of them had been exposed to at least 5 days of
systemic antifungal therapy (breakthrough infections). Skin le-
sions were reported in 12 patients and pneumonia in 19 pa-
tients. The mortality rate attributable to the fungus was found
to be 76%, with 67% of deaths occurring within 10 days of
admission (179).
Critically ill patients admitted to intensive care units and
subjected to invasive medical procedures and antibiotic treat-
ment are the patients most commonly associated with tricho-
sporonosis, other than patients with malignant diseases (24, 25,
44, 154, 191). A recent paper from Chagas-Neto et al. (25)
showed that in a series of 22 Brazilian pediatric and adult
patients with trichosporonosis fungemia, most were ICU pa-
tients with no malignant disease. Most infected patients had
degenerative diseases with organ failures and were subjected
to treatment with broad-spectrum antibiotics and multiple in-
vasive medical procedures before developing fungemia. Crude
mortality rates were 30% for children and 87.5% for adult
patients (P  0.025) (24, 25). Finally, small series of cases of
invasive trichosporonosis have also been described for burn
victims, patients with secondary hemochromathosis, and Job’s
syndrome (23, 26, 73, 162).
Based on these series of cases, it is possible that fungemia
and fever represent the most common clinical findings de-
scribed for Trichosporon hematogenic dissemination. However,
despite being less frequent, there are increasing reports of
episodes of organ-specific infections and patients with dissem-
inated trichosporonosis presenting with pneumonia, soft tissue
lesions and eventually endophthalmitis, endocarditis, brain
abscess, meningitis, arthritis, esophagitis, lymphadenopathy,
liver, splenic abscess, and uterine infections (23, 24, 26, 27, 74,
98, 110, 117, 154, 178).
Peritonitis is one of the most common and serious compli-
cations of peritoneal dialysis, and a case of peritoneal infection
due to Trichosporon spp. in this setting was documented by
Khanna et al. in 1980 (95). Fungal peritonitis is usually docu-
mented in patients with a history of previous bacterial infec-
tions, and this condition presents with sign and symptoms
usually associated with any microorganism causing dialysis-
associated peritonitis: fever, abdominal fullness, and turbid
peritoneal dialysate fluid (88, 111).
Despite being considered rare, endocarditis due to Tricho-
sporon species in native or prosthetic valves of nonneutropenic
patients has been increasingly reported. Patients usually de-
velop large vegetations that may lead to embolic phenomena
frequently located on the aortic bifurcation, in arteries of the
lower extremities, or eventually in the brain. As suggested by
most reports, valve replacement is mandatory, but recurrence
of infection is very common and prognosis is generally poor
regardless of the antifungal therapy (29, 86, 93, 114, 116, 147–
149, 164, 182).
Urinary tract infections by this pathogen may also occur, espe-
cially in patients with urinary obstruction or those undergoing
vesical catheterization and antibiotic treatment. These infections
represent a clinical challenge for clinicians, as there are no clear
and specific indications for the clinical interpretation of Tricho-
sporon sp. recovery in urine. Although unusual, renal damage and
aggravation of renal dysfunction may occur (50, 127, 191).
Although most published reports on Trichosporon dissemi-
nated infections present scarce data in terms of species iden-
tification of the etiological agents using molecular methods, T.
asahii is the most frequently isolated species in these infections
(25, 154, 179).
Finally, Ando et al. have described that the genus Trichosporon,
in addition to causing infections, is the major etiological agent of
summer-type hypersensitivity pneumonitis (SHP) in Japan (5).
The authors investigated 621 patients with SHP and found that
95% of them had anti-Trichosporon antibodies in serum. Tricho-
sporon isolates were found extensively in patients’ houses, and the
elimination of these organisms from patients’ houses prevented
disease (6, 163, 195, 196). Trichosporon species are responsible for
SHP, leading to type III and IV allergies via repeated inhalation
of organic dust and fungal arthroconidia that contaminate home
environments during the hot, humid, and rainy summer season in
western and southern Japan (11, 65, 92, 133, 169, 181, 188, 194).
SHP is an immunologically induced lung disease, with pathogen-
esis mechanisms involving an initial immune complex-mediated
lung injury followed by cell-mediated tissue damage with massive
lymphocyte infiltration into the lungs (90). Mizobe et al. have
characterized the antigenic components involved in SHP as GXM
(124).
T. cutaneum was originally described as the major agent of
SHP, exhibiting 4 different genotypes: I, II, III, and I-III. After
the extensive revision of the taxonomy of Trichosporon spp.,
the taxon T. cutaneum was divided into more than 10 different
species, which tend to be grouped within the previously de-
scribed serotypes (6, 85, 133, 169).
DIAGNOSIS OF INVASIVE TRICHOSPORONOSIS AND
LABORATORY TOOLS FOR IDENTIFICATION OF
TRICHOSPORON SPP.
In accordance with the definitions of opportunistic invasive
fungal infections (IFI) published by the European Organiza-
tion for Research and Treatment of Cancer/Invasive Fungal
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Infection Cooperative Group (EORTC/IFICG) and the Na-
tional Institute of Allergy and Infectious Disease Mycoses
Study Group (NIAID/MSG), invasive trichosporonosis may be
defined as follows (40).
1. “Proven invasive trichosporonosis.” Patients with proven
invasive trichosporonosis presenting at least one of the
following criteria: (i) blood cultures yielding Tricho-
sporon species in patients with temporally related clinical
signs and symptoms of infection, (ii) cerebrospinal fluid
(CSF) cultures yielding Trichosporon species, or (iii) bi-
opsy specimens that are culture positive and present
histopathological evidence of fungal elements compati-
ble with Trichosporon spp.
2. “Probable invasive trichosporonosis.” Patients with
probable invasive trichosporonosis present all of the fol-
lowing criteria: (i) presence of at least one host factor
(therapy with an immunosuppressive drug[s], neutrope-
nia, or persisting fever despite therapy with appropriate
broad-spectrum antibiotics), (ii) one microbiological
criterion (culture or presence of fungal elements com-
patible with Trichosporon in a suspect biological ma-
terial), and (iii) one major clinical criterion (imaging or
cytobiochemical findings) consistent with infection.
As the EORTC/IFICG and NIAID/MSG definitions do not
provide specific indications for the clinical interpretation of
Trichosporon sp. recovery from respiratory tract specimens, we
have adapted the criteria for diagnosis of “probable” pulmo-
nary infection proposed by Girmenia and collaborators (62).
These criteria require the following evidence for diagnosis of
probable pneumonia: the presence of pulmonary infiltrates
and recovery of Trichosporon species from sputum or bron-
choalveolar lavage (BAL) fluid samples in the absence of other
pathogens causing opportunistic infections.
Microbiological diagnosis of superficial and invasive tricho-
sporonosis classically relies on culture findings as well as the
identification of fungal elements compatible with Trichosporon
spp. (hyphae, pseudohyphae, arthroconidia, and blastoconidia)
in wet mount and/or tissue biopsy specimens. Although dem-
onstration of fungal organisms in tissue and cultures is consid-
ered the “gold standard” for defining invasive infections, ob-
taining biopsy specimens may be difficult for some patients.
Consequently, nonculture methods for the diagnosis of inva-
sive mycosis are increasingly needed to surpass the limitations
of test sensitivity, delayed results, and problems in distinguish-
ing between colonized and truly infected patients.
Antigen Detection
The detection of (133)--D-glucan (BDG) has been used
extensively for early diagnosis of invasive fungal infections,
including candidiasis and aspergillosis (136). There are no re-
ports in the English language literature specifically addressing
the sensitivity and specificity of BDG measurement in the
diagnosis of invasive trichosporonosis. However, a recent pub-
lication reported epidemiological and clinical aspects related
to 33 cases of Trichosporon fungemia in Japan (179). In that
study, only 50% of patients had a single test positive for BDG
at the time of admission, and few had an antigen-positive test
prior to their positive blood cultures. Therefore, based on the
experience of this series of cases, it appears that the measure-
ment of BDG levels may have serious limitations for the early
diagnosis of invasive trichosporonosis.
It is well known that Trichosporon strains have GXM in their
cell wall, which can lead to a cross-reaction with C. neoformans
antigens in sera of patients with invasive trichosporonosis
(120). According to Lyman and collaborators, all Trichosporon
strains can produce measurable levels of GXM antigen, and
thus the detection of anticryptococcal cross-reactive antigen
may be an useful tool in the early diagnosis of Trichosporon
infections (109). However, unlike for C. neoformans, the struc-
tural and serological properties of Trichosporon GXM have
been poorly investigated (56). Therefore, considering the lim-
ited clinical information available on this topic, further clinical
studies are necessary to confirm if the detection of Tricho-
sporon GXM by using the Cryptococcus antigen test has poten-
tial for screening patients with invasive trichosporonosis.
PCR-Based Methods
More recently, PCR-based methods and flow cytometry as-
says have been developed to diagnose invasive infection due to
Trichosporon species. Though these new assays are not yet
standardized to be used routinely in clinical settings, they rep-
resent important strategies for future clinical validation.
Nakajima et al. used a PCR technique to amplify the fungal
ITS region. Total DNA was extracted from a lung biopsy spec-
imen taken from a patient suffering from lung cancer. The ITS
amplicon was sequenced, and this fragment identified T. asahii
as the causative agent of the infection (131).
Fungal DNA can be extracted and detected not only from fresh
tissues but also from paraffin-embedded tissue sections. Sano et
al. (158) extracted DNAs from 30 different tissue sections ob-
tained from major organs of 3 autopsy cases of disseminated
trichosporonosis. The fungemic patients had been previously di-
agnosed by blood cultures and analysis with the Vitek 2 compact
system to be infected by T. asahii. Pan-species and species-specific
primer sets were used in nested PCRs to amplify different ampli-
con sizes of the rDNA region: 170 bp, 259 bp, and 412 bp. Out of
30 tissue samples tested, 20 were positive for Trichosporon sp.
infection by hematoxylin and eosin (H&E) staining, and 22 were
positive by detection using Grocott’s stain. PCR amplification of
the 170-bp fragment was positive in 20 of 22 samples, whereas
only 12 of the 22 were positive for the 259-bp fragment. All of the
30 samples were PCR negative for the 412-bp fragment. Of the 8
samples that were negative by Grocott staining, only 1 sample was
positive for both the 170- and 259-bp bands. The authors also
verified that the efficiency of fungal detection by PCR decreased
with longer periods of tissue fixation. After 1 day of fixation, only
one-third of the collected samples were positive by both Grocott
staining and amplification of the 170- and 259-bp bands. Longer
tissue fixation of between 6 and 21 days considerably diminished
the amplification of the 259-bp fragment (2 of 12) (158).
Trichosporon spp. can also be detected from biological fluids
by using PCR assays. Nagai et al. developed a nested PCR
assay to amplify part of the T. asahii 28S rDNA from a collec-
tion of 11 serum samples from patients with histologically
diagnosed disseminated trichosporonosis. Of the 11 samples
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tested, 7 (64%) were PCR positive and 6 were positive for the
GXM antigen (129).
Later, Sugita and collaborators used species-specific primers
to amplify the rDNA region in nested PCRs for T. asahii
diagnosis. A total of 11 serum samples from 7 different patients
with deep-seated trichosporonosis confirmed after autopsy
were tested by PCR assay and latex agglutination (LA) test for
detection of Trichosporon spp. T. asahii DNA was detected by
PCR from 9 of 11 samples, with only 7 samples also positive in
the LA test (173).
Hosoki and collaborators (79) were able to detect break-
through Trichosporon infection using serum PCR with a pa-
tient suffering from cytophagic histiocytic panniculitis and neu-
tropenia. Those authors reported a study in which the patient’s
serum was screened every other week to PCR amplify bands
related to fungal DNA. It was observed that until the third
week after a cord blood transplant, the patient had no funge-
mia. On day 28, when the patient had been receiving prophy-
lactic voriconazole for 17 days, T. asahii DNA was detected in
blood samples, even though blood cultures remained negative.
At that time, the patient had no symptoms, and BDG serum
titers were normal. T. asahii DNA was detected by PCR in this
patient’s blood until day 39; the patient was then cured of the
infection.
To improve the detection and identification of fungal infec-
tions in biological samples, high-throughput technologies, such
as PCR with pan-species primer sets and DNA microarray,
have been applied. Microarray assays were combined with mul-
tiplex PCR of unique ITS1, 18S, and 5.8S sequences and con-
secutive DNA microarray hybridization to diagnose 14 major
fungal pathogens, including T. asahii. Ninety-one samples of
blood, bronchoalveolar lavage fluid, and tissues were analyzed
from 46 neutropenic patients representing 5 cases with no
fungal infection and 5 cases with proven, 3 cases with probable,
and 33 cases with possible IFI. In the single case of invasive
trichosporonosis included in this series, T. asahii could be
positively detected in blood and BAL fluid samples by the
microarray assay (166).
Bottles of blood cultures collected from patients with inva-
sive trichosporonosis have also been used to validate PCR
assays as a tool for the diagnosis of fungemia and the further
identification of the causative fungal species. Hsiue et al. de-
veloped an oligonucleotide array system targeting the ITS1 or
ITS2 region to analyze 116 fungus-positive blood cultures. This
system could identify 16 genera among 77 yeast species and
was able to detect and identify 2 samples of T. asahii in blood
cultures, compared to only one positive identification of Tri-
chosporon spp. by phenotypic methods (82).
More recently, Nagano and collaborators compared culture-
based methods with molecular techniques for the detection of
fungi in 77 adult cystic fibrosis patients. Sputum samples were
collected for DNA extraction, and the ITS region was ampli-
fied for sequencing analysis. Trichosporon spp. were identified
in 2 of 77 samples by molecular techniques, whereas only one
of those two samples was identified by culture methods (130).
Luminex xMAP Technology
A novel flow cytometric technique called Luminex xMAP has
been developed for the detection of medically important species
of fungi. This assay is based on the use of PCR-biotinylated
amplicon target DNA that is inoculated into a microsphere-bead
mixture containing species-specific probes of interest. By adding a
reporter molecule (streptavidin R-phycoerythrin), hybridized spe-
cies-specific amplicons captured by complementary nucleotide
sequences on microsphere beads can be recognized by the fluo-
rescence of the reporter molecules.
Landlinger and collaborators (103) have used the Luminex
xMAP technology to identify fungal species in samples from
peripheral blood, blood cultures, pulmonary infiltrate biopsy
specimens, bronchoalveolar lavage fluid, and bronchotracheal
secretions and from isolated fungal strains. This system utilized
2 pan-Trichosporon probes designed to hybridize to the ITS2
region, which is highly variable among the genomes of individ-
ual fungal species, and it detected at least four clinically rele-
vant Trichosporon species (T. asahii, T. inkin, T. cutaneum, and
T. beigelii). Those authors reported that from one sample of
paraffin-embedded tissue, a Trichosporon sp. was detected by
specific hybridization signals, and following further sequencing
analysis, this species was identified as T. cutaneum.
Not only is this technology useful for analysis of biological
samples, it also has potential for the identification of Tricho-
sporon spp. from culture isolates by using probes that recognize
not only the ITS region and intergenic spacer 1 (IGS1) but also
the D1/D2 region of the 28S rDNA (Fig. 1). Diaz et al. (41)
used the Luminex 100 xMAP assay to identify 39 strains of
different Trichosporon species. They showed that the ITS and
D1/D2 regions were sufficient to discriminate between species
and that the IGS region could differentiate closely related
species such as T. asahii, T. japonicum, and T. asteroides.
New Perspectives on Microscopic Imaging Diagnosis
Microscopic imaging analysis has also been improved in
order to increase the ability to prove deep-seated Trichosporon
spp. infections. Obana et al. (135) compared the performances
of different histopathological stains for identifying fungal cells
in tissues from 9 autopsy cases, including 3 cases of dissemi-
nated trichosporonosis, 3 cases of gastric candidiasis, 2 cases of
pulmonary aspergillosis, and 1 case of pulmonary cryptococ-
cosis. Those authors reported that Trichosporon cells (T. asa-
hii) were weakly detectable within tissue sections compared
with the ability to detect other fungal species when stained with
conventional Grocott’s stain. Using a mucicarmine stain, Tri-
FIG. 1. Schematic structure of the rRNA gene of Trichosporon spp. ITS, internal transcribed spacer; IGS, intergenic spacer region. The total
length of the rDNA locus is approximately 7,850 bp, and the IGS1 region comprises 485 bp.
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chosporon could be weakly stained within the tissues, whereas
Candida and Aspergillus were negatively stained. A colloidal
iron stain, which reacts with Cryptococcus capsules, showed
clear staining of Trichosporon cell walls as well as Cryptococcus
capsules. A periodic acid-methenamine-silver stain (PAM) ap-
peared to best discriminate fungal elements of Trichosporon
spp. in tissue sections. Those authors used transmission elec-
tron microscopy to observe sections stained with Grocott’s
stain and diluted PAM to evaluate putative differences in cell
wall silver deposition between Candida and Trichosporon
strains. This strategy was useful for identifying differences in
hyphal size as well as laminar deposition of silver granules in
the cell wall. In conclusion, the authors suggested that histo-
logical staining procedures and electron microscopy may have
potential as a tool for discriminating tissue infections by Can-
dida and Trichosporon species.
Phenotypic Identification of Trichosporon Species
The taxonomy of Trichosporon spp. has been completely
rewritten, and the genus now includes 50 species (139), at least
16 of which have clinical relevance. This high number of new
species presents a large variability in terms of virulence, clinical
manifestations in humans, and antifungal susceptibility. Con-
sequently, before defining strategies to treat and prevent su-
perficial and fungal infections caused by Trichosporon spp., it is
necessary to accurately identify the causative microorganism at
the species level.
Several methods to identify Trichosporon species have been
reported, including morphological and biochemical tests as
well as molecular tools. Despite the fact that phenotypic meth-
ods are more suitable for routine use in general microbiology
laboratories, the accuracy of the identification of Trichosporon
spp. seems to be limited. Molecular methods are more precise
in species identification but are costly for routine laboratory
use (151, 172).
It is important to note that both Trichosporon and Geotri-
chum species are able to produce arthroconidia. In clinical
laboratory analysis, when arthroconidia are visualized the ure-
ase test is recommended. Unlike Geotrichum spp., all species
of the Trichosporon genus are able to hydrolyze urea (39).
Although these genera are phenotypically similar, they are
genetically very distinct. The ITS nucleotide sequences are less
than 80% similar (33). Subsequently, specific diagnostic PCR
can also be performed to differentiate these two genera (175).
Phenotypic methods for Trichosporon species identification
are based on the characterization of micromorphological as-
pects of colonies as well as biochemical profiling. Performing a
slide microculture to search for arthroconidia is a very useful
tool for the screening of Trichosporon spp. However, other
morphological aspects and biochemical tests do not allow the
complete identification of Trichosporon isolates at the species
level (151, 172). Indeed, by comparing the experiences of 3
different laboratories in evaluating the biochemical and phys-
iological characteristics of 6 clinically relevant Trichosporon
spp., significant discrepancies in the results generated by test-
ing the same organisms were observed in different studies (24,
39, 144, 175). Therefore, one can conclude that classical meth-
ods for yeast identification have limited accuracy and repro-
ducibility for Trichosporon spp. identification.
Despite limitations, several commercial nonautomated and
automated systems have been used in the identification of
Trichosporon spp. Notwithstanding the problems for biochem-
ical tests mentioned above, it is also important to emphasize
that many of these methods do not include new taxonomic
categories in their databases. Consequently, the identification
of the genus Trichosporon is oversimplified due to incomplete
databases and classification keys.
The nonautomated commercial methods most commonly
used for yeast identification in clinical laboratories are sum-
marized below.
1. API 20C AUX (bioMe´rieux, Mercy l’Etoile, France).
The API 20C AUX method is based on the evaluation of
the ability of the fungus to assimilate 19 carbon sources.
It requires additional tests, such as macro- and micro-
morphological observation of colonies and a urease pro-
duction test. The results are read at 48 or 72 h. The
current database includes only 3 species: T. asahii, T.
inkin, and T. mucoides (48, 72, 144, 146).
2. ID 32C (bioMe´rieux, Mercy l’Etoile, France). The ID
32C method is based on the evaluation of the ability of
the fungus to assimilate 24 carbon sources and 5 organic
acids, evaluation of yeast sensitivity to cycloheximide,
and esculin tests. It requires additional observation of
the macro- and micromorphology of the colonies. This
method shows inconsistent identification, and the data-
base includes only T. asahii, T. inkin, and T. mucoides
(18, 144, 146).
3. RapID Yeast Plus system (Innovative Diagnostic Sys-
tem, Norcross, GA). The RapID Yeast Plus system is
based on the observation of 13 enzymatic hydrolysis sub-
strates and assimilation of 5 carbon sources for the iden-
tification of clinically important yeasts (48). Kitch et al.
(97) analyzed the ability of this technique to identify 304
clinical yeast isolates, 3 of which were Trichosporon spp.,
within 4 h. Two out of 3 isolates were identified exclu-
sively as Trichosporon beigelii, though 1 isolate was mis-
identified as C. neoformans.
The automated systems for yeast identification most com-
monly used in clinical laboratories are summarized below. In
general, all of the automated systems have severe limitations
regarding the number of Trichosporon species listed in their
databases.
1. Vitek Systems (bioMe´rieux, Vitek, Hazelwood, MO).
The Vitek Systems system is based on nitrogen and car-
bon assimilation tests, enzymatic tests, and evaluation of
yeast sensitivity to cycloheximide. The test readings are
performed spectrophotometrically by the automated sys-
tem after 24 and 48 h of incubation. The current data-
base (Vitek 2) lists only T. asahii, T. inkin, and T. mu-
coides. Not only is this system limited by the number of
species included in the database, but inconsistent results
have been reported for the identification of T. inkin and
T. asteroides, being erroneously identified as T. asahii by
this system (2, 19, 43, 52, 83).
2. Baxter Microscan (Baxter Microscan, West Sacramento,
CA). The Baxter Microscan method can generate final
reports of yeast identification in 4 h by evaluating the
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enzymatic profile of each organism tested. Fluorometric
and spectrophotometric readings are taken and enriched by
data generated by micro- and macromorphological obser-
vation of colonies. This system is considered to be less
accurate than the Vitek system described above, and sev-
eral authors have experienced difficulties in the correct
identification of Trichosporon spp. using this method due to
limitations in its database. To our knowledge, there has not
been an update to the Microscan database since the origi-
nal publications; therefore, the database still refers to all
Trichosporon spp. as T. beigelii (102, 168).
Most papers addressing the accuracy of commercial yeast
identification methods provide very little data on specific Tri-
chosporon species. Moylett and collaborators claimed to iden-
tify 2 isolates of Trichosporon pullulans as the cause of chronic
granulomatous disease by using the Vitek Yeast Biochemical
card (128). At that time, this card version had only T. beigelii
and T. pullulans in its database. To confirm their findings,
Holland et al. examined the same two strains by amplification
and sequencing of their ITS regions (78). BLAST analysis
revealed that both yeasts initially identified phenotypically as
Trichosporon pullulans were genotypically identified as Crypto-
coccus adeliensis. Ahmad and collaborators used the Vitek 2
system to identify a collection of clinical strains and found 29
isolates that they first identified as T. asahii. After all 29 iden-
tifications were checked by sequencing the ITS regions, 4
strains were reassigned as T. asteroides (2).
More recently, Leaw et al. (105) analyzed the accuracy of
phenotypic tests and molecular markers (ITS1, ITS2, and 28S
D1/D2 regions) for the identification of 373 medically relevant
yeasts encompassing 86 species. A total of 74 strains were
simultaneously identified by the API ID32C system and
molecular methods. Of note, 27 Trichosporon strains repre-
sentative of 9 different species (T. aquatile, T. asahii, T.
cutaneum, T. debeurmannianum, T. dermatis, T. inkin, T.
jirovecii, T. mucoides, and T. pullulans) were included in the
analysis. The first finding of this study was that examination
of the ITS2 region allowed for accurate identification of the
yeast species, while the D1/D2 sequences were too con-
served and could not discriminate between T. dermatis and
T. mucoides. In addition, the authors reported that 4 out 6
T. dermatis clinical isolates were misclassified by biochemi-
cal methods as T. cutaneum.
The limited ability of biochemical tests to provide reliable
identification of clinical isolates of Trichosporon spp. was re-
cently documented by Rodriguez-Tudela et al. (151). They
compared the identification of 49 isolates of Trichosporon spp.
using the amplification and sequencing of the ITS and inter-
genic spacer (IGS) regions with that of 4 different biochemical
tests, including fermentation of different carbon sources,
growth on nitrogen sources, growth at various temperatures,
and the ability to hydrolyze urea. Not surprisingly, 26 isolates
(53%) were misclassified at the species level according to se-
quencing analysis. Out of 15 T. asahii isolates, only 8 were
correctly identified by biochemical tests, while 6 were identi-
fied as T. mucoides and 1 as T. ovoides. All isolates belonging
to the T. jirovecii, T. japonicum, T. montevideense, and T. do-
mesticum species were not able to be identified by classical
identification methodology. However, 6 T. inkin isolates out of
7 were correctly identified by biochemical tests.
Commercial systems based on phenotypic tests to provide
identification of Trichosporon spp. are very limited in their
accuracy because of either the limited number of species in-
cluded in their databases or the inconsistent ability of their
biochemical tests to accurately identify all 50 potential species
within the genera. Considering the limitations of the pheno-
typic methods used to identify Trichosporon spp. at the species
level, it is easy to understand why most reports refer only to the
genus Trichosporon without determining the species or simply
identify clinical isolates as T. asahii or non-T. asahii.
The lack of accurate laboratory tools for the complete iden-
tification of Trichosporon strains in clinical laboratories impairs
the understanding of unique epidemiological and clinical fea-
tures of these strains. This technical deficiency also impairs the
ability to understand differences in clinical responses to con-
ventional antifungal therapy, possibly related to the medically
important species of this genus, previously named T. beigelii
(10, 141, 185, 186).
Molecular Targets and Identification of Trichosporon
Species in Cultures
PCR-based methods. DNA-based methods have been exten-
sively used for the accurate identification of Trichosporon spp.
(142). Indeed, the evaluation of specific nucleotide sequences
can be a precise method to resolve taxonomic problems gen-
erated by the inconsistent phenotypic identification of Tricho-
sporon species. In this regard, ribosomal genes represent par-
ticularly consistent evaluative markers and include alternating
conserved regions (D1/D2 region of the 28S rDNA) and vari-
able regions (ITS and IGS1 regions) that may be useful for
species identification and phylogenetic studies (Fig. 1) (171,
175). Apparently, a combination of at least 2 of those mark-
ers should be used for the proper molecular identification
of Trichosporon strains and analysis of their phylogenetic
relationships.
Sugita et al. (175) constructed a phylogenetic tree using the
small-subunit (SSU) region sequences of rDNAs from differ-
ent pathogenic yeasts obtained from DNA libraries. The
primer pair TRF and TRR, which amplifies part of the SSU
region, was designed for the specific identification of the genus
Trichosporon because these oligonucleotides do not amplify
conserved regions in the ribosomal genes of other medically
important yeasts besides Trichosporon.
Subsequently, Sugita et al. (174) have sequenced and ana-
lyzed the interspacer region (ITS1 and ITS2) genes of the
rDNA from Trichosporon spp. and proposed 17 species and
five varieties for this genus. Therefore, these authors con-
cluded that the six medically relevant species could be accu-
rately identified by their ITS sequences.
However, Sugita et al. (172) also analyzed the sequences of
IGS1, which is localized between the 26S and 5S rDNA genes,
in 25 isolates of Trichosporon. The IGS1 regions ranged in size
from 195 bp to 704 bp. Comparative analysis of the nucleotide
sequences suggested higher variation in the IGS1 region than
in the ITS region. Therefore, the use of ITS region sequencing
was considered unsuitable for the identification of the large
number of recently described species of Trichosporon. In ad-
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dition, these authors were also able to identify 5 different
genotypes of T. asahii among 43 strains (172). Following this
work, several others have reported the use of the IGS region to
accurately identify Trichosporon spp. in cultures from several
biological samples, such as skin, nails, urine, sputum, biopsy
samples, and blood (25, 89, 104, 151, 169).
Based on the ITS1 and ITS2 sequences, Leaw et al. (104)
developed an oligonucleotide array to identify 77 species of
clinically relevant yeasts belonging to 16 genera. Probes for
each yeast species were designed and included probes to iden-
tify T. aquatile, T. asahii, T. cutaneum, T. inkin, and T. pullu-
lans, as well as a pan-probe for the identification of T. asahii,
T. aquatile, and T. inkin. Those authors screened a collection of
452 yeast strains and verified that the array had 100% sensi-
tivity and 97% specificity. There were 17 Trichosporon sp. type
strains and 4 T. cutaneum clinical isolates included in the
collection to validate the array and 4 other species, (T. derma-
tis, T. jirovecii, T. mucoides, and T. ovoides) to test the assay
specificity. The authors concluded that all Trichosporon spp.
tested were correctly identified except for T. ovoides, which
cross-hybridized with the pan-probe (104).
More recently, Makino et al. (112) used a real-time quanti-
tative PCR (qPCR) assay to identify and quantify 9 yeast spe-
cies, including T. asahii and T. jirovecii, in dairy product sam-
ples. They amplified conserved sequences of 28S rDNA D1/D2
domains with 6 primer sets and were able to identify all isolates
that artificially contaminated fermented milk within a 5-h as-
say. These tools and DNA markers were useful for yeast iden-
tification and could possibly be used as a first screening tool for
Trichosporon species in biological samples.
Other molecular markers have been tested for use in the
identification of Trichosporon species. Biswas et al. (20) ana-
lyzed the sequences of the mitochondrial cytochrome b (cyt b)
genes from 23 different fungal strains representing 42 species.
They amplified a 396-bp fragment and observed that there
were 141 variable nucleotide sites (35.6%) among Tricho-
sporon strains. Twenty-two strains (from 11 different species)
contained introns in their sequences. Analysis of the deduced
protein sequences of the 396-bp fragments showed 34 variable
amino acid sites (25.75%). T. domesticum, T. montevideense, T.
asahii, T. asteroides, T. gracile, and T. guehoae all had identical
amino acid sequences. Phylogenetic analysis revealed that all
species of Trichosporon except T. montevideense and T. domes-
ticum included species-specific cyt b genes. Using this ap-
proach, two isolates were then identified: Trichosporon sp.
strain CBS 5581 was identified as T. pullulans, and the clinical
isolate IFM 48794 was identified as T. faecale (20).
Proteomics as a tool for fungal identification. During the
past few years, protein fingerprints have been used as genus
and species signatures to discriminate among isolates and
identify pathogens (58). Protein fingerprint analysis by mass
spectrometry (MS), in which the protein content of a certain
sample within a complex mixture is analyzed, is a widely
used technique in proteomics studies. Mass spectrum pro-
files are acquired by mixing the samples with a matrix in
which peptides are ionized using a laser. Thereafter, pep-
tides are expelled from the metal target by high voltage and
travel in a vacuum tube to be finally analyzed according to
their mass/charge ratio (m/z). This technique typically gen-
erates spectra of the most abundant proteins, ranging from
1,000 to 20,000 Da. The process to identify microorganisms
in culture, including automated identification, is based on
the matching of peaks from fingerprints deposited in a da-
tabase, e.g., the matrix-assisted laser desorption ionization–
time of flight (MALDI-TOF) MS BioTyper system (Bruker
Daltonics), with the peaks of the spectrum generated from
the clinical sample. The more similar two spectra are, the
more reliable is the match, and therefore, genus or species
identification is obtained (21).
The MALDI BioTyper 2.0 software possesses more than
3,700 mass spectrum profiles in its database. Of those profiles,
274 are from fungi and 11 are related to Trichosporon spp. Of
these 11, 6 are T. asahii, T. cutaneum, T. debeurmannianum, T.
inkin, T. mucoides, and T. ovoides and 2 are Trichosporon sp.
Another feature of this method is the time required for sample
processing. One isolate can be processed and identified in less
than 2 min, making this tool the next generation in microor-
ganism identification (58).
Marklein and collaborators (115) have identified 285 iso-
lates of medically important yeasts, including 3 isolates of T.
cutaneum, using MALDI-TOF MS. Overall, the system
identified 247 of the clinical isolates (92.5%); the remaining
20 isolates were identified only after complementation of
the database with protein spectra representative of all type
strains. All 3 isolates of T. cutaneum were properly identi-
fied by the API ID 32C system but not by the MALDI-TOF
MS due to the absence of a reference protein spectrum
characteristic for this species. After generation of a refer-
ence type spectrum for T. cutaneum, all 3 isolates were
appropriately identified.
Recently, Bader et al. (13) tested the accuracy of MALDI-TOF
MS using 2 different commercially available systems, MALDI
BioTyper2 (Bruker Daltonics) and Saramis (AnagnosTec), for
the identification of 1,192 clinical yeast isolates previously
identified by morphological characterization and biochemical
tests (API 20 C AUX and ID 32 C galleries). The congruence
among all three identification methods was 95.1%, and all 4
isolates of T. asahii were properly identified by these three
procedures.
Stevenson et al. (167) constructed a yeast mass spectrum
library using the MALDI BioTyper2 (Bruker Daltonics) soft-
ware. One hundred twenty-four type strains were initially eval-
uated for construction of the protein spectrum database li-
brary, but 15 were removed due to unacceptable spectra or
discordant identification results after DNA sequencing, which
occurred with 1 T. asahii strain and 3 T. ovoides strains. In
order to validate the accuracy of the database library, 194
clinical isolates (23 species covering 6 genera) were tested, and
192 (99.0%) of the clinical isolates were properly identified by
MALDI-TOF MS (ID score of1.8), including 4 isolates of T.
asahii, 1 of T. coremiiforme, and 3 of T. mucoides. MALDI-
TOF MS should be considered a reliable technique to rapidly
identify fungal species and may be used as an alternative to
PCR-based methods, with the additional advantage of the lack
of complicated DNA extraction (167).
It is therefore evident that the use of molecular methods to
evaluate specific DNA sequences or proteins fingerprints is
now considered mandatory to accurately identify strains be-
longing to the genus Trichosporon. Small clinical laboratories
unable to run those tests should send their strains to reference
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laboratories to have the Trichosporon strains properly identi-
fied at the species level, particularly when such strains are
obtained from deep-seated infections.
Genotyping of Trichosporon spp., with an emphasis on the
geographic distribution of T. asahii genotypes. T. asahii is the
most commonly isolated species from patients with invasive
trichosporonosis and presents up to 9 different genotypes de-
scribed around the globe, using the IGS1 sequence as the
molecular marker (24, 119).
Sugita et al. were the first to describe 5 T. asahii genotypes,
based on the diversity of the IGS1 sequences exhibited by T.
asahii strains obtained from Japan, the United States, and
Brazil (172). They found that among isolates obtained in Ja-
pan, 26 (87%) were genotype 1 or 3, while the others belonged
to genotypes 2 and 4. The 13 T. asahii strains originally from
the United States were representative of either genotype 3 or
genotype 5, and the single Brazilian isolate was identified as
genotype 3. No genotype 1 strains were found among the 13
North American strains tested.
Unlike the observations made with patients with superficial
and invasive trichosporonosis, Sugita et al. reported that most
T. asahii strains isolated from the homes of patients suffering
with summer-type hypersensitivity pneumonitis were genotype
3, instead of genotype 1, which is predominant in patients. In
the same study, those authors described 2 new genotypes of T.
asahii, genotypes 6 and 7, both documented in patients with
fungemia (169).
Rodriguez-Tudela et al. (152) also evaluated sequence poly-
morphisms of the IGS1 regions of T. asahii strains isolated from
patients in Argentina, Brazil, and Spain. The authors were able to
recognize 6 different genotypes within the collection of 18 T.
asahii strains. The majority of the strains were representative of
genotypes 1 and 5. Spanish strains exhibited all other genotypes,
with the exception of genotype 2, whereas the 5 South American
isolates belonged to genotypes 1 and 6 (152).
Chagas-Neto and collaborators analyzed the genotype dis-
tribution of 15 T. asahii isolates obtained from blood samples
from patients in Brazil and found that the majority of these
strains belonged to genotype 1 (86.7%). Only one isolate each
belonged to genotypes 3 and 4, representing the first descrip-
tion of genotype 4 reported in a patient in South America (25).
Recently, two papers described the geographic distribution
pattern of T. asahii genotypes in Turkey and Thailand based on
IGS1 sequences (Fig. 2). Kalkanci et al. reported that among
87 T asahii clinical isolates from Turkey, genotype 1 was rep-
resented by 69 strains (79.3%), followed by genotypes 5 (7
strains, 8.0%), 3 (6 strains, 6.9%), 6 (3 strains, 3.4%), and 4 (1
strains, 1.1%) (89). By examining the genotyping of T. asahii
strains performed worldwide, those authors noted that geno-
type 7 has been found only in Japan and that genotype 8 and
the novel genotype 9 were described only in Turkey. Mekha et
al. evaluated 101 T asahii strains in Thailand and found that
genotype 1 (45 strains, 44.5%) was predominant, followed by
genotypes 3 (35 strains, 34.7%) and 6 (18 strains, 17.8%) (119).
Figure 2 summarizes the worldwide distribution of T asahii
strains obtained only from patients with superficial and inva-
sive Trichosporon infections (25, 89, 119, 152, 169, 172). It is
important to note that, with the exception of Turkey, Thailand,
and Japan, a limited number (usually 30) of T. asahii strains
have been genotyped in most studies published in the English
language literature. Genotype 1 is the most abundant type of T.
asahii strain in all regions, ranging from approximately 45 to
80%, except for the United States where it has never been
identified. Genotypes 3 and 5 predominate in U.S. medical
centers. Further studies are needed to clarify whether different
genotypes of T. asahii isolates may present different features in
terms of virulence, tissue tropism, or antifungal susceptibility.
ANTIFUNGAL SUSCEPTIBILITY TESTING FOR
TRICHOSPORON SPP. AND PRINCIPLES
OF THERAPY
Despite the increasing occurrence of invasive Trichosporon
infections refractory to conventional antifungal drugs, there
are few studies investigating the in vitro susceptibilities of clin-
ical strains of Trichosporon spp. to antifungal compounds. Dif-
ficulties in species identification within the genus and the lack
of standardized sensitivity tests in vitro contribute to the lim-
ited information available on this topic (24, 140).
Antifungal Susceptibility Tests
The Clinical and Laboratory Standards Institute (CLSI) doc-
ument describing antifungal susceptibility testing of yeasts does
not specifically address the genus Trichosporon. However, most
available studies evaluating the susceptibility of Trichosporon
FIG. 2. Distribution of T. asahii genotypes, based on IGS1 sequences of clinical isolates, in the United States, Spain, Brazil, Thailand, Japan,
and Turkey (25, 89, 119, 152, 169, 172).
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spp. to antifungal drugs in vitro use the CLSI broth microdilu-
tion method currently (2008) standardized for Candida spp.
and C. neoformans (10, 132) or an adaptation of the European
Committee for Antimicrobial Susceptibility Testing (EU-
CAST) broth microdilution method, a recommendation origi-
nally proposed for the genus Candida (36).
Despite the fact that the CLSI methodology may be success-
fully adapted to test Trichosporon strains, several authors have
suggested that the broth microdilution method is not satisfac-
tory for detecting isolates resistant to amphotericin B, as it
generates a narrow MIC variation within different clinical
strains. Therefore, MIC breakpoints have not yet been estab-
lished for amphotericin B assays (41, 49).
The majority of the studies examining sensitivity tests of
Trichosporon spp. use the outdated nomenclature T. beigelii
(28, 75, 141, 185). Therefore, sensitivities to antifungal drugs
within different species of the genus Trichosporon are largely
still not investigated. After the resolution of the genus Tricho-
sporon, some authors have suggested that T. asahii is more
resistant to amphotericin B and more sensitive to triazoles
than other Trichosporon species (80, 89, 190).
Rodriguez-Tudela et al. (151) accurately identified 49 Tri-
chosporon clinical isolates using IGS region sequencing and
tested their susceptibility to antifungal drugs. Those authors
demonstrated that all T. asahii isolates tested had amphoteri-
cin B MICs of 2 g/ml. They also observed that the majority
of T. coremiiforme and T. faecale strains were also resistant to
amphotericin B, whereas the other species tested had MICs of
1 g/ml. In a recent study coordinated by the same group,
voriconazole and posaconazole were shown to be the 2 new
antifungal drugs with the best in vitro antifungal activity against
most Trichosporon spp. (8).
Chagas-Neto et al. (25) evaluated the in vitro activities for 22
bloodstream Trichosporon strains using the CLSI broth mi-
crodilution test. The authors found that the geometric means
of MICs generated by triazoles against Trichosporon spp. were
generally lower than those values obtained with amphotericin
B. Voriconazole generated the lowest MIC values against all
clinical strains (25).
Ruan et al. (154) evaluated the in vitro activities of 9 differ-
ent antifungal drugs against 43 clinical isolates of Trichosporon
species using broth microdilution. Voriconazole exhibited ex-
cellent in vitro activity against most of the strains tested, in-
cluding isolates resistant to fluconazole. All isolates appeared
to be resistant in vitro to all echinocandins. The authors con-
cluded that most strains exhibited relatively high MIC values
against amphotericin B.
Antifungal Therapy
Despite the increasing relevance of the genus Trichosporon
in contemporary medicine, the treatment of patients with tri-
chosporonosis remains a challenge, as there are few data avail-
able on the in vitro and in vivo activities of antifungal drugs
against clinically relevant species of the genus.
Superficial infections occasionally respond to topical anti-
fungal agents, but white piedra may reoccur after suspension of
the antimycotic. Consequently, some studies suggest that treat-
ment of this disease should consist of hair removal followed by
topical and/or oral antifungal therapy (96).
There are increasing data suggesting that amphotericin B
has limited in vitro and in vivo activity against Trichosporon
spp., including T. asahii strains (183, 193). Amphotericin B
MIC values against Trichosporon spp., particularly T. asahii,
are generally incompatible with serum levels normally achiev-
able in patients receiving a conventional formulation of this
polyene. Although some isolates can be inhibited by low con-
centrations of amphotericin B, fungicidal activity has not been
observed in animal models or in neutropenic patients (3, 24,
25, 143, 179, 186, 189, 190).
In a study of 25 neutropenic patients who developed sys-
temic trichosporonosis and were treated with amphotericin B,
only four survived (81). Girmenia et al. reported the clinical
outcomes for 55 patients with hematological diseases and dis-
seminated trichosporonosis who were treated with amphoter-
icin B. A clinical response to amphotericin B was documented
in only 13/55 (24%) of the patients evaluated (62).
Triazoles seem to have better in vitro and in vivo antifungal
activities against Trichosporon spp. than amphotericin B. Flu-
conazole was used as the initial therapy in 85% of 19 patients
with invasive trichosporonosis documented in a single medical
center in Taiwan, and the mortality rate was 42% (154). Suzuki
et al. recently evaluated the clinical and therapeutic aspects of
33 cases of Trichosporon fungemia documented in patients
with hematological malignancies. The authors clearly demon-
strated that survival was longer for patients treated with an
azole than for those treated with other drugs (179).
Voriconazole also has excellent in vitro activity against Tri-
chosporon strains and may be useful for treating patients with
trichosporonosis, including cases of acute leukemia and my-
elodysplasic syndrome with disseminated infection (12, 57, 106,
118, 140, 160).
Regarding the therapeutic role of 5-fluorocytosine (5FC) in
trichosporonosis, the available data are limited and controver-
sial. In vitro data suggest that a large proportion of Tricho-
sporon strains may be less susceptible or resistant to 5FC (25,
119). In contrast, some authors report good results in the
treatment of trichosporonosis with combination therapy with
5FC and amphotericin B (62). Consequently, at this time, we
do not have substantial clinical data to safely recommend the
utilization of 5FC to treat invasive trichosporonosis.
Finally, echinocandins alone have little to no activity against
Trichosporon spp. and are not recommended for tricho-
sporonosis treatment (188). Breakthrough Trichosporon infec-
tions have been reported in patients treated with echinocan-
dins (caspofungin and micafungin) (35, 47, 188). Interestingly,
a combination of echinocandin with amphotericin B or azoles
appears to have some in vitro and in vivo synergistic antifungal
effects (14, 161).
SUMMARY AND CONCLUSION
Trichosporon spp. are basidiomycetous yeast-like anamor-
phic organisms, found in tropical and temperate areas of the
globe and are widely distributed in nature. Although most
Trichosporon strains isolated in clinical laboratories are re-
lated to episodes of colonization or superficial infections,
this fungus has been recognized as an opportunistic agent
causing emergent, invasive infections in tertiary care hospi-
tals worldwide.
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Invasive Trichosporon spp. have been documented mostly in
cancer patients and in critically ill patients exposed to multiple
invasive medical procedures. It is possible that the ability of
Trichosporon strains to adhere to and form biofilms on im-
planted devices may account for the progress of invasive tri-
chosporonosis, since this ability promotes escape from drugs
and host immune responses. In addition, the presence of glucu-
ronoxylomannan (GXM) in the cell walls of Trichosporon spp.
and their ability to produce proteases and lipases are all factors
likely related to the virulence of this genus.
The outdated taxon T. beigelii was replaced by several sep-
arate species, and the taxonomy of the genus was progressively
modified by powerful molecular tools able to discriminate be-
tween phylogenetically closely related species. Currently, 50
different species of Trichosporon have been described by dif-
ferent authors, and 16 can cause human disease. Globally, T.
asahii is the most common species causing invasive tricho-
sporonosis and presents 9 different genotypes, based on the
IGS1 sequence, that exhibit substantial variability in their geo-
graphic distribution worldwide.
Phenotypic methods for Trichosporon species identifica-
tion are based on the characterization of micromorpholog-
ical aspects of colonies and biochemical profiling. Perform-
ing a slide microculture to search for arthroconidia and
testing for urease production are useful tools for the screen-
ing of Trichosporon spp. However, morphological aspects
and biochemical tests do not allow the complete identifica-
tion of Trichosporon isolates at the species level. Conse-
quently, molecular methods, including sequencing of the
IGS region, are necessary to obtain accurate results for the
identification of Trichosporon strains.
Diagnosis of invasive trichosporonosis may be a challenge,
and several molecular methods have been developed in the last
2 decades, including PCR-based methods, Luminex xMAP
technology (a novel flow cytometry technique with potential
for the detection of medically important species of fungi), and
proteomics.
Despite the increasing relevance of the genus Trichosporon
in contemporary medicine, treating patients with tricho-
sporonosis remains a challenge given that we have little data
available on the in vitro and in vivo activities of antifungal drugs
against clinically relevant species of the genus.
In conclusion, disseminated trichosporonosis has been in-
creasingly reported worldwide and represents a challenge for
both diagnosis and species identification. Prognosis is limited,
and antifungal regimens containing triazoles appear to be the
best therapeutic approach. In addition, removal of central ve-
nous lines and control of underlying conditions should be con-
sidered to optimize clinical outcomes.
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